In 2006, the National Hepatitis B Epidemiological Survey showed that there are 20-30 million patients with chronic hepatitis B in China. Among them, some chronic hepatitis B patients will develop liver failure, nearly 1/4 of chronic hepatitis B patients may develop cirrhosis, and 3-6% of cirrhotic patients will also develop liver cancer. Every year, 300,000 people die from liver failure, cirrhosis and liver cancer caused by hepatitis B virus, so it is important to avoid liver failure and stop the progression to cirrhosis and even liver cancer. The treatment of chronic hepatitis B should be based on the patient’s specific situation and adopt a comprehensive treatment plan, including reasonable rest and nutrition, adjustment of mind, restoration of liver function, regulation of immunity, anti-virus, anti-fibrosis and other treatments. Recent studies have shown that the replication and extent of hepatitis B virus is the most important risk factor for disease progression. In other words, the higher the concentration of HBV DNA, the higher the percentage of development of cirrhosis and liver cancer. Therefore, in the treatment of chronic hepatitis B, antiviral therapy is the key. The Guidelines for the Prevention and Treatment of Hepatitis B emphasize that “standardized antiviral therapy should be administered whenever indicated and allowed.” Antiviral therapy can reduce transmission, reduce liver damage, reduce or delay the occurrence of cirrhosis, liver failure or liver cancer, and ultimately improve quality of life and extend life expectancy. Anti-viral treatment for hepatitis B strives to achieve three effects: first, restoration of liver function and maximum suppression or clearance of the virus; second, serological transformation, conversion of major triplets to minor triplets; and third, surface antigen conversion. The first two are easier to achieve, while the third effect is more difficult to achieve, so most patients may need long-term treatment, and patients with cirrhosis and liver cancer generally need lifelong medication. However, we should have confidence in the treatment, because most of the hepatitis B can be controlled, and the efficacy of antiviral therapy for chronic hepatitis B can also be achieved in the efforts of doctors and patients, standardized individualized treatment to achieve the best therapeutic effect. The current standardized antiviral therapy treatment mainly includes the following points: 1, master the indications: not all patients with chronic hepatitis B need antiviral therapy, and not all patients with chronic hepatitis B are suitable for antiviral therapy. If chronic hepatitis B virus carriers with normal liver function and no liver histology are blindly treated with antiviral therapy, it is often difficult to be effective; while antiviral therapy for inactive hepatitis B surface antigen carriers is not only a waste of medical resources, but also increases the pain, stress and economic burden of patients. Therefore, both doctors and patients should follow our Guidelines and proceed with treatment carefully. Those with viral replication in the body along with inflammatory activity in the liver should be treated. In addition, age, health status, treatment history and availability of antiviral drugs should be considered in treatment. 2, standardized drug selection, individualized treatment: Currently, there are only two types of drugs officially approved by the State Drug Administration for anti-hepatitis B virus treatment: interferon and nucleoside (acid) analogs. However, each drug has its own characteristics, and each patient’s condition is different, so the choice of which drug to choose should be based on a combination of factors. The actual fact is that you can find a lot of people who are not able to get a good deal on a lot of things. 3, adhere to the treatment, with a full course of treatment, grasp the “end”: chronic hepatitis B antiviral treatment to complete the course of treatment, in order to maximize the lasting inhibition of hepatitis B virus replication, to avoid virus mutation drug resistance, to achieve the goal of controlling disease progression, prevent the occurrence of cirrhosis and liver cancer. Therefore, every patient receiving antiviral therapy should be prepared for long-term treatment. It is important to take medication on time and not to interrupt or change medication arbitrarily to avoid virus mutation and drug resistance, relapse or even deterioration of the disease as much as possible. In case you can afford it, extend the course of treatment as much as possible to get the best results. 4, to regularly monitor: chronic hepatitis B treatment process, must be regularly monitored to dynamically understand the efficacy and safety of drugs, to estimate the prognosis. The patient with interferon should be tested monthly for routine blood, blood sugar, thyroid function, kidney function and ALT, HBeAg positive patients should be checked for HBeAg and anti-HBe, HBVDNA at 12 weeks, 24 weeks, 48 weeks and 24 weeks after treatment. nucleoside (acid) drugs should be checked at least once every 3 months for HBVDNA, ALT and hepatitis B two pairs of half, etc. to observe The efficacy of treatment; also test renal function, creatine kinase, electrocardiogram, etc. If the viral load and/or disease rebound during treatment, the virus should be tested for mutation and drug resistance, and once there is mutation, the treatment plan should be adjusted in time to reduce the harm of viral resistance. If antiviral treatment does the above four things, it not only helps to control the disease, improve the efficacy of antiviral treatment, reduce the patient’s pain and hospitalization rate; but also can reduce the occurrence of viral drug-resistant mutations and reduce the patient’s psychological burden and economic burden.